PRE-FUNDED COMMON STOCK PURCHASE WARRANT SUNSHINE BIOPHARMA, INC.Sunshine Biopharma, Inc • May 16th, 2023 • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 15, 2023 (the “Issue Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), up to __________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 16th, 2023 • Sunshine Biopharma, Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2023, between Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 16th, 2023 • Sunshine Biopharma, Inc • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 12, 2023, between Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
AEGIS CAPITAL CORP.Sunshine Biopharma, Inc • May 16th, 2023 • Pharmaceutical preparations • New York
The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed private placement (the “Placement”) by Sunshine Biopharma, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units considered at the market under Nasdaq listing rules, with each unit consisting of one (1) share of common stock and two (2) warrants (“Warrants”), each to one (1) share of common stock exercisable at the Nasdaq at- the-market price of the common stock or consisting of one pre-funded warrant to purchase one (1) share of common stock and two (2) Warrants (collectively, the “Securities”). This placement agent agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company
COMMON STOCK PURCHASE WARRANT SUNSHINE BIOPHARMA, INC.Sunshine Biopharma, Inc • May 16th, 2023 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 16, 2023 (the “Issue Date”) and on or prior to 5:00 p.m. (New York City time) on November 16, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
